Base de dados : MEDLINE
Pesquisa : H01.770.644.145.675 [Categoria DeCS]
Referências encontradas : 7779 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 778 ir para página                         

  1 / 7779 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28455696
[Au] Autor:Mentis AA; Dardiotis E; Grigoriadis N; Petinaki E; Hadjigeorgiou GM
[Ad] Endereço:Department of Microbiology, University Hospital of Larissa, University of Thessaly, Larissa, Greece. amentis1@jhu.edu.
[Ti] Título:Viruses and Multiple Sclerosis: From Mechanisms and Pathways to Translational Research Opportunities.
[So] Source:Mol Neurobiol;54(5):3911-3923, 2017 Jul.
[Is] ISSN:1559-1182
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Viruses are directly or indirectly implicated in multiple sclerosis (MS). Here, we review the evidence on the virus-related pathophysiology of MS, introduce common experimental models, and explore the ways in which viruses cause demyelination. By emphasizing knowledge gaps, we highlight future research directions for effective MS diagnostics and therapies: (i) identifying biomarkers for at-risk individuals, (ii) searching for direct evidence of specific causative viruses, (iii) establishing the contribution of host genetic factors and viruses, and (iv) investigating the contribution of immune regulation at extra-CNS sites. Research in these areas is likely to be facilitated by the application of high-throughput technologies, the development of systems-based bioinformatic approaches, careful selection of experimental models, and the acquisition of high-quality clinical material for tissue-based research.
[Mh] Termos MeSH primário: Esclerose Múltipla/virologia
Pesquisa Médica Translacional
[Mh] Termos MeSH secundário: Animais
Modelos Animais de Doenças
Progressão da Doença
Seres Humanos
Modelos Biológicos
Esclerose Múltipla/patologia
Esclerose Múltipla/fisiopatologia
Células-Tronco/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170430
[St] Status:MEDLINE
[do] DOI:10.1007/s12035-017-0530-6


  2 / 7779 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28461524
[Au] Autor:Krueger JG; Kirkham B; Ritchlin CT
[Ad] Endereço:From Clinical Investigation, The Rockefeller University, New York; Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, New York, USA; Guy's and St. Thomas' UK National Health Service (NHS) Foundation Trust; King's College London, London, UK.
[Ti] Título:Basic and Translational Science: A Report from the GRAPPA 2016 Annual Meeting.
[So] Source:J Rheumatol;44(5):679-683, 2017 May.
[Is] ISSN:0315-162X
[Cp] País de publicação:Canada
[La] Idioma:eng
[Ab] Resumo:Rapid advances in effective treatments for psoriasis and psoriatic arthritis (PsA) have emerged from improved understanding of cell subsets and critical mediators that promote tissue inflammation and destruction. More specifically, increased knowledge of innate immunity and the important involvement of cytokines in the interleukin (IL)-23-IL-17 axis as key mediators of psoriatic plaque and joint inflammation in both psoriasis and PsA have led to new theories of immunopathogenesis. Herein we summarize recent discussions on IL-17-related pathways and their relationship to psoriasis and PsA.
[Mh] Termos MeSH primário: Artrite Psoriásica/patologia
Psoríase/patologia
Pesquisa Médica Translacional
[Mh] Termos MeSH secundário: Dermatologia
Seres Humanos
Inflamação/patologia
Reumatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.3899/jrheum.170143


  3 / 7779 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28460639
[Au] Autor:Furuya H; Brenner D; Rosser CJ
[Ad] Endereço:Clinical and Translational Research Program, University of Hawaii Cancer Center, 701 Ilalo St, Rm 327, Honolulu, HI, 96813, USA.
[Ti] Título:On the brink of extinction: the future of translational physician-scientists in the United States.
[So] Source:J Transl Med;15(1):88, 2017 May 01.
[Is] ISSN:1479-5876
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Over the past decade, we have seen an unparalleled growth in our knowledge of cancer biology and the translation of this biology into a new generation of therapeutic tools that are changing cancer treatment outcomes. With the continued explosion of new biologic discoveries, we find ourselves with a limited number of trained and engaged translational physician-scientists capable of bridging the chasm between basic science and clinical science. Here, we discuss the current state translational physician-scientists find themselves in and offer solutions to navigate during this difficult time.
[Mh] Termos MeSH primário: Médicos
Pesquisadores
Pesquisa Médica Translacional
[Mh] Termos MeSH secundário: Seres Humanos
National Institutes of Health (U.S.)
Apoio à Pesquisa como Assunto
Estados Unidos
[Pt] Tipo de publicação:EDITORIAL
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.1186/s12967-017-1188-6


  4 / 7779 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453734
[Au] Autor:Hausenloy DJ; Garcia-Dorado D; Bøtker HE; Davidson SM; Downey J; Engel FB; Jennings R; Lecour S; Leor J; Madonna R; Ovize M; Perrino C; Prunier F; Schulz R; Sluijter JPG; Van Laake LW; Vinten-Johansen J; Yellon DM; Ytrehus K; Heusch G; Ferdinandy P
[Ad] Endereço:The Hatter Cardiovascular Institute, University College London, 67 Chenies Mews, London WC1E 6HX, UK; The National Institute of Health Research University College London Hospitals Biomedical Research Centre, 149 Tottenham Court Road London, W1T 7DN, UK; Cardiovascular and Metabolic Disorders Program
[Ti] Título:Novel targets and future strategies for acute cardioprotection: Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart.
[So] Source:Cardiovasc Res;113(6):564-585, 2017 May 01.
[Is] ISSN:1755-3245
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Ischaemic heart disease and the heart failure that often results, remain the leading causes of death and disability in Europe and worldwide. As such, in order to prevent heart failure and improve clinical outcomes in patients presenting with an acute ST-segment elevation myocardial infarction and patients undergoing coronary artery bypass graft surgery, novel therapies are required to protect the heart against the detrimental effects of acute ischaemia/reperfusion injury (IRI). During the last three decades, a wide variety of ischaemic conditioning strategies and pharmacological treatments have been tested in the clinic-however, their translation from experimental to clinical studies for improving patient outcomes has been both challenging and disappointing. Therefore, in this Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart, we critically analyse the current state of ischaemic conditioning in both the experimental and clinical settings, provide recommendations for improving its translation into the clinical setting, and highlight novel therapeutic targets and new treatment strategies for reducing acute myocardial IRI.
[Mh] Termos MeSH primário: Cardiologia/métodos
Fármacos Cardiovasculares/uso terapêutico
Ponte de Artéria Coronária/efeitos adversos
Insuficiência Cardíaca/prevenção & controle
Precondicionamento Isquêmico/métodos
Traumatismo por Reperfusão Miocárdica/prevenção & controle
Intervenção Coronária Percutânea/efeitos adversos
Infarto do Miocárdio com Supradesnível do Segmento ST/terapia
Pesquisa Médica Translacional/métodos
[Mh] Termos MeSH secundário: Animais
Cardiologia/normas
Fármacos Cardiovasculares/efeitos adversos
Ponte de Artéria Coronária/normas
Modelos Animais de Doenças
Insuficiência Cardíaca/etiologia
Insuficiência Cardíaca/patologia
Insuficiência Cardíaca/fisiopatologia
Seres Humanos
Pós-Condicionamento Isquêmico/métodos
Precondicionamento Isquêmico/efeitos adversos
Precondicionamento Isquêmico/normas
Precondicionamento Isquêmico Miocárdico/métodos
Traumatismo por Reperfusão Miocárdica/etiologia
Traumatismo por Reperfusão Miocárdica/patologia
Traumatismo por Reperfusão Miocárdica/fisiopatologia
Intervenção Coronária Percutânea/normas
Fatores de Proteção
Fatores de Risco
Infarto do Miocárdio com Supradesnível do Segmento ST/complicações
Infarto do Miocárdio com Supradesnível do Segmento ST/patologia
Infarto do Miocárdio com Supradesnível do Segmento ST/fisiopatologia
Pesquisa Médica Translacional/normas
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRACTICE GUIDELINE; REVIEW
[Nm] Nome de substância:
0 (Cardiovascular Agents)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1093/cvr/cvx049


  5 / 7779 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28460160
[Au] Autor:Huot P; Sgambato-Faure V; Fox SH; McCreary AC
[Ad] Endereço:Centre de Recherche du Centre Hospitalier de l'Université de Montréal , Montreal, QC H2X 0A9, Canada.
[Ti] Título:Serotonergic Approaches in Parkinson's Disease: Translational Perspectives, an Update.
[So] Source:ACS Chem Neurosci;8(5):973-986, 2017 05 17.
[Is] ISSN:1948-7193
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Parkinson's disease (PD) has long been seen as a disorder caused by degeneration of the dopaminergic system, leading to the classic motor manifestations of the disease. However, there is now overwhelming evidence that PD is more than a disease merely caused by dopamine depletion. It is well-known that a myriad of other neurotransmitters are affected by the disease process. One such neurotransmitter is serotonin (5-HT). 5-HT has been shown to play a role in several motor and nonmotor manifestations of PD, including tremor, cognition, depression and psychosis. 5-HT also seems to play a critical role in L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. A breadth of preclinical studies and clinical trials have been conducted that aimed at modulating the 5-HT system in order to alleviate depression, cognitive deficits, psychosis, and dyskinesia. In this Review, we summarize recent advances in the 5-HT field in PD, but with a translational emphasis. We start by presenting a novel nonhuman primate model of PD that presents with dual dopamine and 5-HT lesions. We then present preclinical and clinical data that introduce new concepts, such as the use of biased and partial agonists, as well as molecules recently introduced to the field of PD, such as eltoprazine, pimavanserin, nelotanserin, and SYN-120, to enhance therapeutic benefit while minimizing adverse events, notably on parkinsonian disability.
[Mh] Termos MeSH primário: Antiparkinsonianos/uso terapêutico
Doença de Parkinson/metabolismo
Serotoninérgicos/uso terapêutico
Serotonina/metabolismo
[Mh] Termos MeSH secundário: Animais
Antiparkinsonianos/farmacologia
Modelos Animais de Doenças
Seres Humanos
Atividade Motora/efeitos dos fármacos
Doença de Parkinson/tratamento farmacológico
Serotoninérgicos/farmacologia
Pesquisa Médica Translacional
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antiparkinson Agents); 0 (Serotonin Agents); 333DO1RDJY (Serotonin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE
[do] DOI:10.1021/acschemneuro.6b00440


  6 / 7779 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27779110
[Au] Autor:Eliade M; Skrzypski J; Baurand A; Jacquot C; Bertolone G; Loustalot C; Coutant C; Guy F; Fumoleau P; Duffourd Y; Arnould L; Delignette A; Padéano MM; Lepage C; Raichon-Patru G; Boudrant A; Bône-Lépinoy MC; Villing AL; Charpin A; Peignaux K; Chevrier S; Vegran F; Ghiringhelli F; Boidot R; Sevenet N; Lizard S; Faivre L
[Ad] Endereço:Centre of Genetic, Children Hospital, CHU, Dijon, France.
[Ti] Título:The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
[So] Source:Oncotarget;8(2):1957-1971, 2017 Jan 10.
[Is] ISSN:1949-2553
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Until recently, the molecular diagnosis of hereditary breast and ovarian cancer (HBOC) was mostly based on BRCA1/2 testing. Next generation sequencing and the recent discovery of new genes involved in HBOC now permit the transfer of genomic capture targeting multiple candidate genes from research to clinical use. However, the implications for the management of patients and their families have not been extensively studied, in particular since some of these genes are not well-established cancer predisposing genes. We studied 583 consecutive patients from Burgundy (France) fulfilling the criteria for BRCA testing using a next generation sequencing 25-genes panel including 20 well-established high-risk cancer genes as well as more recently identified predisposing HBOC cancer. A pathogenic BRCA1/2 mutation was found in 51 patients (9%). Besides, we found 37 pathogenic or likely pathogenic mutations in 10 different high to low-risk genes in 34 patients (6%). The most frequently mutated genes were CHEK2 (n = 12; 2%), ATM (n = 9; 1.5%), and PALB2 (n = 4; 0.6%). Three patients had a mutation in two different predisposing genes. The analysis of clinical actionability conducted in mutation-positive individuals revealed that additional disease-specific screening and/or prevention measures beyond those based on personal and family history alone had been recommended in 69% of cases. In conclusion, multigene panel testing is a powerful tool to identifying high to low-risk HBOC susceptibility genes. The penetrance and spectrum of cancers with these other genes are sometimes undefined, and further collaborative work is crucial to address this question.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/genética
Testes Genéticos
Síndrome Hereditária de Câncer de Mama e Ovário/diagnóstico
Padrões de Prática Médica
Transcriptoma
Pesquisa Médica Translacional
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Estudos de Coortes
Prática Clínica Baseada em Evidências
Feminino
França/epidemiologia
Regulação Neoplásica da Expressão Gênica
Frequência do Gene
Predisposição Genética para Doença
Testes Genéticos/métodos
Testes Genéticos/normas
Testes Genéticos/estatística & dados numéricos
Síndrome Hereditária de Câncer de Mama e Ovário/genética
Sequenciamento de Nucleotídeos em Larga Escala
Seres Humanos
Masculino
Meia-Idade
Linhagem
Relações Médico-Paciente
Guias de Prática Clínica como Assunto/normas
Padrões de Prática Médica/normas
Padrões de Prática Médica/estatística & dados numéricos
Relações Profissional-Família
Pesquisa Médica Translacional/normas
Pesquisa Médica Translacional/estatística & dados numéricos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.18632/oncotarget.12699


  7 / 7779 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27771012
[Au] Autor:Soellner R; Lenartz N; Rudinger G
[Ad] Endereço:Institut für Psychologie, Universität Hildesheim, Universitätsplatz 1, D-31141 Hildesheim, Germany. Electronic address: soellner@uni-hildesheim.de.
[Ti] Título:Concept mapping as an approach for expert-guided model building: The example of health literacy.
[So] Source:Eval Program Plann;60:245-253, 2017 02.
[Is] ISSN:1873-7870
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Concept mapping served as the starting point for the aim of capturing the comprehensive structure of the construct of 'health literacy.' Ideas about health literacy were generated by 99 experts and resulted in 105 statements that were subsequently organized by 27 experts in an unstructured card sorting. Multidimensional scaling was applied to the sorting data and a two and three-dimensional solution was computed. The three dimensional solution was used in subsequent cluster analysis and resulted in a concept map of nine "clusters": (1) self-regulation, (2) self-perception, (3) proactive approach to health, (4) basic literacy and numeracy skills, (5) information appraisal, (6) information search, (7) health care system knowledge and acting, (8) communication and cooperation, and (9) beneficial personality traits. Subsequently, this concept map served as a starting point for developing a "qualitative" structural model of health literacy and a questionnaire for the measurement of health literacy. On the basis of questionnaire data, a "quantitative" structural model was created by first applying exploratory factor analyses (EFA) and then cross-validating the model with confirmatory factor analyses (CFA). Concept mapping proved to be a highly valuable tool for the process of model building up to translational research in the "real world".
[Mh] Termos MeSH primário: Análise por Conglomerados
Alfabetização em Saúde
Modelos Teóricos
Projetos de Pesquisa
Inquéritos e Questionários/normas
[Mh] Termos MeSH secundário: Comportamento Cooperativo
Pesquisa Empírica
Processos Grupais
Seres Humanos
Reprodutibilidade dos Testes
Pesquisa Médica Translacional/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  8 / 7779 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29393306
[Au] Autor:Willey C; Fede J; Stevenson J; Hayward A; Kogut S; Fournier H; Padbury J
[Ad] Endereço:Professor, Department of Pharmacy Practice, University of Rhode Island.
[Ti] Título:Clinical and Translational Research in Rhode Island: Results of a Needs Assessment Survey.
[So] Source:R I Med J (2013);101(1):21-25, 2018 Feb 02.
[Is] ISSN:2327-2228
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The Advance-Clinical and Translational Research (CTR) program was established in Rhode Island in May of 2016 with an IDeA Program Infrastructure award to collaborating institutions: Brown University, the University of Rhode Island, with the Lifespan, Care New England and Providence VA Medical Center healthcare institutions and the Rhode Island Quality Institute. To support programmatic planning, the Tracking and Evaluation Key Component Activity (KCA) of Advance-CTR developed and implemented a needs assessment survey to identify the obstacles to clinical and translational research at the participating institutions. We describe the methods used and the responses, which identified needs for study design and data analysis support. Support for project development, pilot funding and grants administration showed significant variation, depending on the affiliation of the respondent. The results of the survey are discussed in the context of Rhode Island's significant opportunities to support and develop the capabilities of scientists who engage in translational research. [Full article available at http://rimed.org/rimedicaljournal-2018-02.asp].
[Mh] Termos MeSH primário: Ensaios Clínicos como Assunto/organização & administração
Determinação de Necessidades de Cuidados de Saúde
Pesquisa Médica Translacional/organização & administração
[Mh] Termos MeSH secundário: Atitude do Pessoal de Saúde
Feminino
Pesquisas sobre Serviços de Saúde
Seres Humanos
Satisfação no Emprego
Masculino
Pesquisa Qualitativa
Apoio à Pesquisa como Assunto
Rhode Island
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE


  9 / 7779 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29326244
[Au] Autor:Dunbar CE; High KA; Joung JK; Kohn DB; Ozawa K; Sadelain M
[Ad] Endereço:Hematology Branch, National Heart, Lung and Blood Institute, Bethesda, MD, USA. dunbarc@nhlbi.nih.gov m-sadelain@ski.mskcc.org.
[Ti] Título:Gene therapy comes of age.
[So] Source:Science;359(6372), 2018 01 12.
[Is] ISSN:1095-9203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:After almost 30 years of promise tempered by setbacks, gene therapies are rapidly becoming a critical component of the therapeutic armamentarium for a variety of inherited and acquired human diseases. Gene therapies for inherited immune disorders, hemophilia, eye and neurodegenerative disorders, and lymphoid cancers recently progressed to approved drug status in the United States and Europe, or are anticipated to receive approval in the near future. In this Review, we discuss milestones in the development of gene therapies, focusing on direct in vivo administration of viral vectors and adoptive transfer of genetically engineered T cells or hematopoietic stem cells. We also discuss emerging genome editing technologies that should further advance the scope and efficacy of gene therapy approaches.
[Mh] Termos MeSH primário: Terapia Genética
[Mh] Termos MeSH secundário: Animais
Edição de Genes
Técnicas de Transferência de Genes
Doenças Genéticas Inatas/terapia
Engenharia Genética
Terapia Genética/efeitos adversos
Vetores Genéticos
Doenças Hematológicas/terapia
Seres Humanos
Neoplasias/terapia
Doenças Neuromusculares/terapia
Pesquisa Médica Translacional
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180207
[Lr] Data última revisão:
180207
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180113
[St] Status:MEDLINE


  10 / 7779 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463656
[Au] Autor:Kane AE; Ayaz O; Ghimire A; Feridooni HA; Howlett SE
[Ad] Endereço:Pharmacology Department, Dalhousie University, Halifax, NS B3H 4H7, Canada.
[Ti] Título:Implementation of the mouse frailty index.
[So] Source:Can J Physiol Pharmacol;95(10):1149-1155, 2017 Oct.
[Is] ISSN:1205-7541
[Cp] País de publicação:Canada
[La] Idioma:eng
[Ab] Resumo:Frailty is considered a state of high vulnerability for adverse health outcomes for people of the same age. Those who are frail have higher mortality, worse health outcomes, and use more health care services than those who are not frail. Despite this, little is known about the biology of frailty, the effect of frailty on pharmacological or surgical outcomes, and potential interventions to attenuate frailty. In humans, frailty can be quantified using a frailty index (FI) based on the principle of deficit accumulation. The recent development of an FI in naturally ageing mice provides an opportunity to conduct frailty research in a validated preclinical model. The mouse FI has been successfully used across a wide range of applications; however, there are some factors that should be considered in implementing this tool. This review summarises the current literature, presents some original data, and suggests areas for future research on the current applications of the mouse FI, inter-rater reliability of the FI, the effect of observer characteristics and environmental factors on mouse FI scores, and the individual items that make up the FI assessment. The implementation of this tool into preclinical frailty research should greatly accelerate translational research in this important field.
[Mh] Termos MeSH primário: Técnicas de Apoio para a Decisão
Fragilidade/diagnóstico
Pesquisa Médica Translacional/métodos
[Mh] Termos MeSH secundário: Fatores Etários
Envelhecimento
Animais
Modelos Animais de Doenças
Meio Ambiente
Seres Humanos
Camundongos
Variações Dependentes do Observador
Valor Preditivo dos Testes
Fatores de Risco
Índice de Gravidade de Doença
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180205
[Lr] Data última revisão:
180205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.1139/cjpp-2017-0025



página 1 de 778 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde